⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
globenewswire.com
ARQT
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
globenewswire.com
ARQT
THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
prnewswire.com
ABBV
JNJ
ARQT
BMY
LLY
INCY
SNY
REGN
PFE
UCB
BIIB
ORGN
TAK
ELMD
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
globenewswire.com
ARQT
The Credibility Filter Wall Street Uses to Sort Biotech Winners
globenewswire.com
ARQT
ANVS
STOK
NTLA
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
globenewswire.com
ARQT
PVLA
INCY
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
ARQT
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
ARQT
Stratum Biosciences Secures $2M Seed Round to Accelerate AI-Powered Skin Biology Discovery and Expanded R&D Partnerships
prnewswire.com
NVDA
ARQT
JNJ
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
ARQT